The Glucose-Sensitive Nanocarrier Based on Phenylboronic Acid

Abstract

Recently, diabetes mellitus has become one of the most serious diseases that threat to human health and even life following cancer and cardiovascular disease. Thus, the developments of efficient insulin administration exhibit great practical significance. However, insulin, which could low blood concentration rapidly, cannot be oral delivery due to very low oral bioavailability for the pure absorption through the gastrointestinal epithelium as well as the rapid hydrolytic and enzymatic degradation in contact with the gastrointestinal fluids. While the frequent administration of exogenous insulin by injection everyday is not perfect due to the inevitable pain, which will cause inflammation, lumps and nodules. In recently, the glucose-responsive insulin delivery system (GRIDS) is developing rapidly which not only has high bioavailability of insulin but also extenuates the pain of diabetics caused by frequent insulin injection. GRIDS is expected to be a promising therapy approach to replace the frequent insulin injection administration. Therefore, the exploited intelligent glucose-responsive insulin delivery system has significant practical application for diabetes treatment.